HIV testing outside of the study among men who have sex with men participating in an hiv vaccine efficacy trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 294-298

  Gust, Deborah A ^a   Wiegand, Ryan E ^a   Para, Michael ^b   Chen, Robert T ^a   Bartholow, Brad N ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Differential risk behavior; HIV test; HIV vaccine clinical trial; Lost to follow up

Indexed keywords

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FOLLOW UP; HEALTH BEHAVIOR; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SELF REPORT; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE;

AIDS SERODIAGNOSIS; AIDS VACCINES; BIOMEDICAL RESEARCH; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MOTIVATION; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70349706024     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ab6e93     Document Type: Article

References (14)

1. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2004;37: 1385-1392.
2. SAS version 9.1.3 [package insert]. Cary, NC: SAS Institute Inc; 2004.
3. Fitzmaurice GM, Laird NM. Generalized linear mixture models for handling nonignorable dropouts in longitudinal studies. Biostatistics. 2000;1:141-156.
4. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125-137. (Pubitemid 19030705)
5. Horton NJ, Bebchuk JD, Jones CL, et al. Goodness-of-fit for GEE: an example with mental health service utilization. Stat Med. 1999;18: 213-222.
6. Bartholow BN, MacQueen KM, Douglas JM Jr, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.
7. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:266-271.
8. Divine B, Greby S, Hunt K, et al. Revised guidelines for HIV counseling, testing and referral. MMWR Morb Mortal Wkly Rep. 2001;50(RR19): 1-58.
9. Hedlund J. Risky business: safety regulations, risk compensation, and individual behavior. Inj Prev. 2000;6:82-90.
10. Melton GB, Levine RJ, Koocher GP, et al. Community consultation in socially sensitive research. Lessons from clinical trials of treatments for AIDS. Am Psychol. 1988;43:573-581.
11. Karlowski TR, Chalmers TC, Frenkel LD, et al. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA. 1975;231: 1038-1042.
12. Branson B, Handsfield H, Janssen R, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep. 2006;55(RR-14):1-17.
13. Johnson MO. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr. 1999;21:413-416.
14. Swartzman LC, Burkell J. Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. Clin Pharmacol Ther. 1998;64:1-7.